Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 13:13Michael Cahillane: Three-Buffy-Coat Platelets – Strengthening Blood Supply Resilience
-
Oct 28, 2026, 13:05N. Mariana S. Vasquez: Antiplatelets vs Anticoagulants – Key Clinical Differences
-
Oct 28, 2026, 12:45Panithaya Chareonthaitawee: A Podcast Walk Through Anticoagulation
-
Oct 28, 2026, 11:55Natalia C. Badillo: Anticoagulation in AF – A Decision Beyond the Score
-
Oct 28, 2026, 08:40Simon Fletcher: The Hidden Burden of Non-Severe Haemophilia
-
Oct 28, 2026, 08:08Paul Agwu: A Low Platelet Count Is Not a Diagnosis – It Is a Clue
-
Oct 28, 2026, 07:54Ifeanyichukwu Ifechidere: When Normal Results Don’t Explain the Bleeding
-
Oct 28, 2026, 06:06Thirunavukkarasu Angappan: Anti-TFPI Antibodies and an Antithrombin-Lowering Drug
-
Oct 28, 2026, 05:52Reegan Burnell-Clarke: Pegcetacoplan and the Evolving Treatment Landscape of PNH